JOURNAL OF ETHNOPHARMACOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2111434, encodeId=d53221114341d, content=偏重的研究方向：中药单体药理 经验分享：请问各位友友这个杂志是什么流程啊怎么编辑从执行编辑—主编—副主编需要这么多编辑审稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a138155158, createdName=ms5000000077211829, createdTime=Wed Jan 25 21:33:06 CST 2023, time=2023-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161584, encodeId=b9132161584f2, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物信息学;动物实验;中药复方 经验分享：投了好多次补了很多实验目前接收了具体时间点为下 2023.9.3 提交 9.29 小修 10.4提交修改稿 10.6接收很看重中药复方的质控化学成分的分析和鉴定最低要求必须有HPLC 图谱复方中药的毒性需要明确急毒实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2feb5587016, createdName=wangc, createdTime=Sun Oct 08 17:52:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2260544, encodeId=74ad2260544a3, content=偏重的研究方向：中药复方机制 经验分享：投一篇中一篇，根本拒不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Apr 15 12:43:49 CST 2025, time=2025-04-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252794, encodeId=82452252e94e5, content=with editor一周了，有没有今年投递的小伙伴, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85169632338, createdName=ms3000001370467208, createdTime=Thu Feb 20 13:25:13 CST 2025, time=2025-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2256895, encodeId=76de225689544, content=请问大家：这个期刊是不是单剂量的中药复方不接收？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc45461785, createdName=ms2000000962134399, createdTime=Thu Mar 20 11:56:19 CST 2025, time=2025-03-20, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1208777, encodeId=de211208e77b8, content=投稿12天了还没有with editor，但是我看拒稿好像很快，是不是没有马上拒都有希望呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/062436adbbcd4e2e890574558d3f2ea4/da27de86c40c4ffa9df1b63d464f7910.jpg, createdBy=884a5513476, createdName=姚爪爪, createdTime=Tue Apr 05 15:28:37 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2255354, encodeId=00ee225535403, content=请问一下这个杂志版面费是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36fa1655811, createdName=1ddd9b98m24(暂无匿称), createdTime=Sun Mar 09 20:44:10 CST 2025, time=2025-03-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2254997, encodeId=dfc0225499e5b, content=偏重的研究方向：网络药理学;中药单体;体内外验证 经验分享：请问编辑让提供质量控制数据，但是是商业化的制剂，已经作为补充文件上传了，但是被编辑退回啦，还是同样的问题，有遇到过的前辈么？要怎么解决呀？还有期刊的参靠文献是什么呀？endnote调正过后还是不对, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50b89577247, createdName=ms2000000503637753, createdTime=Fri Mar 07 10:37:36 CST 2025, time=2025-03-07, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2203530, encodeId=366922035303f, content=请问中药来源的小分子化合物被指出不符合5项规则，要怎么修改，编辑说可以修改后重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6b89216027, createdName=ms8000001555903844, createdTime=Wed May 08 21:11:43 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向：靶点;单体 经验分享：with editor2周多了，要不要催？最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省)]

2023-01-25 ms5000000077211829 来自山东省

偏重的研究方向：中药单体药理
经验分享：请问各位友友这个杂志是什么流程啊怎么编辑从执行编辑—主编—副主编需要这么多编辑审稿嘛

68 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2111434, encodeId=d53221114341d, content=偏重的研究方向：中药单体药理 经验分享：请问各位友友这个杂志是什么流程啊怎么编辑从执行编辑—主编—副主编需要这么多编辑审稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a138155158, createdName=ms5000000077211829, createdTime=Wed Jan 25 21:33:06 CST 2023, time=2023-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161584, encodeId=b9132161584f2, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物信息学;动物实验;中药复方 经验分享：投了好多次补了很多实验目前接收了具体时间点为下 2023.9.3 提交 9.29 小修 10.4提交修改稿 10.6接收很看重中药复方的质控化学成分的分析和鉴定最低要求必须有HPLC 图谱复方中药的毒性需要明确急毒实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2feb5587016, createdName=wangc, createdTime=Sun Oct 08 17:52:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2260544, encodeId=74ad2260544a3, content=偏重的研究方向：中药复方机制 经验分享：投一篇中一篇，根本拒不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Apr 15 12:43:49 CST 2025, time=2025-04-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252794, encodeId=82452252e94e5, content=with editor一周了，有没有今年投递的小伙伴, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85169632338, createdName=ms3000001370467208, createdTime=Thu Feb 20 13:25:13 CST 2025, time=2025-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2256895, encodeId=76de225689544, content=请问大家：这个期刊是不是单剂量的中药复方不接收？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc45461785, createdName=ms2000000962134399, createdTime=Thu Mar 20 11:56:19 CST 2025, time=2025-03-20, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1208777, encodeId=de211208e77b8, content=投稿12天了还没有with editor，但是我看拒稿好像很快，是不是没有马上拒都有希望呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/062436adbbcd4e2e890574558d3f2ea4/da27de86c40c4ffa9df1b63d464f7910.jpg, createdBy=884a5513476, createdName=姚爪爪, createdTime=Tue Apr 05 15:28:37 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2255354, encodeId=00ee225535403, content=请问一下这个杂志版面费是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36fa1655811, createdName=1ddd9b98m24(暂无匿称), createdTime=Sun Mar 09 20:44:10 CST 2025, time=2025-03-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2254997, encodeId=dfc0225499e5b, content=偏重的研究方向：网络药理学;中药单体;体内外验证 经验分享：请问编辑让提供质量控制数据，但是是商业化的制剂，已经作为补充文件上传了，但是被编辑退回啦，还是同样的问题，有遇到过的前辈么？要怎么解决呀？还有期刊的参靠文献是什么呀？endnote调正过后还是不对, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50b89577247, createdName=ms2000000503637753, createdTime=Fri Mar 07 10:37:36 CST 2025, time=2025-03-07, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2203530, encodeId=366922035303f, content=请问中药来源的小分子化合物被指出不符合5项规则，要怎么修改，编辑说可以修改后重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6b89216027, createdName=ms8000001555903844, createdTime=Wed May 08 21:11:43 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向：靶点;单体 经验分享：with editor2周多了，要不要催？最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省)]

2023-10-08 wangc 来自吉林省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：生物信息学;动物实验;中药复方
经验分享：投了好多次补了很多实验目前接收了具体时间点为下 2023.9.3 提交 9.29 小修 10.4提交修改稿 10.6接收很看重中药复方的质控化学成分的分析和鉴定最低要求必须有HPLC 图谱复方中药的毒性需要明确急毒实验

256 18

展开18条回复

[GetPortalCommentsPageByObjectIdResponse(id=2111434, encodeId=d53221114341d, content=偏重的研究方向：中药单体药理 经验分享：请问各位友友这个杂志是什么流程啊怎么编辑从执行编辑—主编—副主编需要这么多编辑审稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a138155158, createdName=ms5000000077211829, createdTime=Wed Jan 25 21:33:06 CST 2023, time=2023-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161584, encodeId=b9132161584f2, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物信息学;动物实验;中药复方 经验分享：投了好多次补了很多实验目前接收了具体时间点为下 2023.9.3 提交 9.29 小修 10.4提交修改稿 10.6接收很看重中药复方的质控化学成分的分析和鉴定最低要求必须有HPLC 图谱复方中药的毒性需要明确急毒实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2feb5587016, createdName=wangc, createdTime=Sun Oct 08 17:52:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2260544, encodeId=74ad2260544a3, content=偏重的研究方向：中药复方机制 经验分享：投一篇中一篇，根本拒不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Apr 15 12:43:49 CST 2025, time=2025-04-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252794, encodeId=82452252e94e5, content=with editor一周了，有没有今年投递的小伙伴, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85169632338, createdName=ms3000001370467208, createdTime=Thu Feb 20 13:25:13 CST 2025, time=2025-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2256895, encodeId=76de225689544, content=请问大家：这个期刊是不是单剂量的中药复方不接收？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc45461785, createdName=ms2000000962134399, createdTime=Thu Mar 20 11:56:19 CST 2025, time=2025-03-20, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1208777, encodeId=de211208e77b8, content=投稿12天了还没有with editor，但是我看拒稿好像很快，是不是没有马上拒都有希望呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/062436adbbcd4e2e890574558d3f2ea4/da27de86c40c4ffa9df1b63d464f7910.jpg, createdBy=884a5513476, createdName=姚爪爪, createdTime=Tue Apr 05 15:28:37 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2255354, encodeId=00ee225535403, content=请问一下这个杂志版面费是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36fa1655811, createdName=1ddd9b98m24(暂无匿称), createdTime=Sun Mar 09 20:44:10 CST 2025, time=2025-03-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2254997, encodeId=dfc0225499e5b, content=偏重的研究方向：网络药理学;中药单体;体内外验证 经验分享：请问编辑让提供质量控制数据，但是是商业化的制剂，已经作为补充文件上传了，但是被编辑退回啦，还是同样的问题，有遇到过的前辈么？要怎么解决呀？还有期刊的参靠文献是什么呀？endnote调正过后还是不对, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50b89577247, createdName=ms2000000503637753, createdTime=Fri Mar 07 10:37:36 CST 2025, time=2025-03-07, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2203530, encodeId=366922035303f, content=请问中药来源的小分子化合物被指出不符合5项规则，要怎么修改，编辑说可以修改后重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6b89216027, createdName=ms8000001555903844, createdTime=Wed May 08 21:11:43 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向：靶点;单体 经验分享：with editor2周多了，要不要催？最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省)]

2025-04-15 第五先生来自浙江省

偏重的研究方向：中药复方机制
经验分享：投一篇中一篇，根本拒不了

7 0

[GetPortalCommentsPageByObjectIdResponse(id=2111434, encodeId=d53221114341d, content=偏重的研究方向：中药单体药理 经验分享：请问各位友友这个杂志是什么流程啊怎么编辑从执行编辑—主编—副主编需要这么多编辑审稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a138155158, createdName=ms5000000077211829, createdTime=Wed Jan 25 21:33:06 CST 2023, time=2023-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161584, encodeId=b9132161584f2, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物信息学;动物实验;中药复方 经验分享：投了好多次补了很多实验目前接收了具体时间点为下 2023.9.3 提交 9.29 小修 10.4提交修改稿 10.6接收很看重中药复方的质控化学成分的分析和鉴定最低要求必须有HPLC 图谱复方中药的毒性需要明确急毒实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2feb5587016, createdName=wangc, createdTime=Sun Oct 08 17:52:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2260544, encodeId=74ad2260544a3, content=偏重的研究方向：中药复方机制 经验分享：投一篇中一篇，根本拒不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Apr 15 12:43:49 CST 2025, time=2025-04-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252794, encodeId=82452252e94e5, content=with editor一周了，有没有今年投递的小伙伴, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85169632338, createdName=ms3000001370467208, createdTime=Thu Feb 20 13:25:13 CST 2025, time=2025-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2256895, encodeId=76de225689544, content=请问大家：这个期刊是不是单剂量的中药复方不接收？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc45461785, createdName=ms2000000962134399, createdTime=Thu Mar 20 11:56:19 CST 2025, time=2025-03-20, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1208777, encodeId=de211208e77b8, content=投稿12天了还没有with editor，但是我看拒稿好像很快，是不是没有马上拒都有希望呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/062436adbbcd4e2e890574558d3f2ea4/da27de86c40c4ffa9df1b63d464f7910.jpg, createdBy=884a5513476, createdName=姚爪爪, createdTime=Tue Apr 05 15:28:37 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2255354, encodeId=00ee225535403, content=请问一下这个杂志版面费是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36fa1655811, createdName=1ddd9b98m24(暂无匿称), createdTime=Sun Mar 09 20:44:10 CST 2025, time=2025-03-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2254997, encodeId=dfc0225499e5b, content=偏重的研究方向：网络药理学;中药单体;体内外验证 经验分享：请问编辑让提供质量控制数据，但是是商业化的制剂，已经作为补充文件上传了，但是被编辑退回啦，还是同样的问题，有遇到过的前辈么？要怎么解决呀？还有期刊的参靠文献是什么呀？endnote调正过后还是不对, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50b89577247, createdName=ms2000000503637753, createdTime=Fri Mar 07 10:37:36 CST 2025, time=2025-03-07, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2203530, encodeId=366922035303f, content=请问中药来源的小分子化合物被指出不符合5项规则，要怎么修改，编辑说可以修改后重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6b89216027, createdName=ms8000001555903844, createdTime=Wed May 08 21:11:43 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向：靶点;单体 经验分享：with editor2周多了，要不要催？最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省)]

2025-02-20 ms3000001370467208 来自江苏省

with editor一周了，有没有今年投递的小伙伴

23 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2111434, encodeId=d53221114341d, content=偏重的研究方向：中药单体药理 经验分享：请问各位友友这个杂志是什么流程啊怎么编辑从执行编辑—主编—副主编需要这么多编辑审稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a138155158, createdName=ms5000000077211829, createdTime=Wed Jan 25 21:33:06 CST 2023, time=2023-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161584, encodeId=b9132161584f2, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物信息学;动物实验;中药复方 经验分享：投了好多次补了很多实验目前接收了具体时间点为下 2023.9.3 提交 9.29 小修 10.4提交修改稿 10.6接收很看重中药复方的质控化学成分的分析和鉴定最低要求必须有HPLC 图谱复方中药的毒性需要明确急毒实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2feb5587016, createdName=wangc, createdTime=Sun Oct 08 17:52:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2260544, encodeId=74ad2260544a3, content=偏重的研究方向：中药复方机制 经验分享：投一篇中一篇，根本拒不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Apr 15 12:43:49 CST 2025, time=2025-04-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252794, encodeId=82452252e94e5, content=with editor一周了，有没有今年投递的小伙伴, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85169632338, createdName=ms3000001370467208, createdTime=Thu Feb 20 13:25:13 CST 2025, time=2025-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2256895, encodeId=76de225689544, content=请问大家：这个期刊是不是单剂量的中药复方不接收？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc45461785, createdName=ms2000000962134399, createdTime=Thu Mar 20 11:56:19 CST 2025, time=2025-03-20, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1208777, encodeId=de211208e77b8, content=投稿12天了还没有with editor，但是我看拒稿好像很快，是不是没有马上拒都有希望呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/062436adbbcd4e2e890574558d3f2ea4/da27de86c40c4ffa9df1b63d464f7910.jpg, createdBy=884a5513476, createdName=姚爪爪, createdTime=Tue Apr 05 15:28:37 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2255354, encodeId=00ee225535403, content=请问一下这个杂志版面费是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36fa1655811, createdName=1ddd9b98m24(暂无匿称), createdTime=Sun Mar 09 20:44:10 CST 2025, time=2025-03-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2254997, encodeId=dfc0225499e5b, content=偏重的研究方向：网络药理学;中药单体;体内外验证 经验分享：请问编辑让提供质量控制数据，但是是商业化的制剂，已经作为补充文件上传了，但是被编辑退回啦，还是同样的问题，有遇到过的前辈么？要怎么解决呀？还有期刊的参靠文献是什么呀？endnote调正过后还是不对, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50b89577247, createdName=ms2000000503637753, createdTime=Fri Mar 07 10:37:36 CST 2025, time=2025-03-07, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2203530, encodeId=366922035303f, content=请问中药来源的小分子化合物被指出不符合5项规则，要怎么修改，编辑说可以修改后重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6b89216027, createdName=ms8000001555903844, createdTime=Wed May 08 21:11:43 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向：靶点;单体 经验分享：with editor2周多了，要不要催？最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省)]

2025-03-20 ms2000000962134399 来自山西省

请问大家：这个期刊是不是单剂量的中药复方不接收？

14 0

[GetPortalCommentsPageByObjectIdResponse(id=2111434, encodeId=d53221114341d, content=偏重的研究方向：中药单体药理 经验分享：请问各位友友这个杂志是什么流程啊怎么编辑从执行编辑—主编—副主编需要这么多编辑审稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a138155158, createdName=ms5000000077211829, createdTime=Wed Jan 25 21:33:06 CST 2023, time=2023-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161584, encodeId=b9132161584f2, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物信息学;动物实验;中药复方 经验分享：投了好多次补了很多实验目前接收了具体时间点为下 2023.9.3 提交 9.29 小修 10.4提交修改稿 10.6接收很看重中药复方的质控化学成分的分析和鉴定最低要求必须有HPLC 图谱复方中药的毒性需要明确急毒实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2feb5587016, createdName=wangc, createdTime=Sun Oct 08 17:52:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2260544, encodeId=74ad2260544a3, content=偏重的研究方向：中药复方机制 经验分享：投一篇中一篇，根本拒不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Apr 15 12:43:49 CST 2025, time=2025-04-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252794, encodeId=82452252e94e5, content=with editor一周了，有没有今年投递的小伙伴, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85169632338, createdName=ms3000001370467208, createdTime=Thu Feb 20 13:25:13 CST 2025, time=2025-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2256895, encodeId=76de225689544, content=请问大家：这个期刊是不是单剂量的中药复方不接收？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc45461785, createdName=ms2000000962134399, createdTime=Thu Mar 20 11:56:19 CST 2025, time=2025-03-20, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1208777, encodeId=de211208e77b8, content=投稿12天了还没有with editor，但是我看拒稿好像很快，是不是没有马上拒都有希望呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/062436adbbcd4e2e890574558d3f2ea4/da27de86c40c4ffa9df1b63d464f7910.jpg, createdBy=884a5513476, createdName=姚爪爪, createdTime=Tue Apr 05 15:28:37 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2255354, encodeId=00ee225535403, content=请问一下这个杂志版面费是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36fa1655811, createdName=1ddd9b98m24(暂无匿称), createdTime=Sun Mar 09 20:44:10 CST 2025, time=2025-03-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2254997, encodeId=dfc0225499e5b, content=偏重的研究方向：网络药理学;中药单体;体内外验证 经验分享：请问编辑让提供质量控制数据，但是是商业化的制剂，已经作为补充文件上传了，但是被编辑退回啦，还是同样的问题，有遇到过的前辈么？要怎么解决呀？还有期刊的参靠文献是什么呀？endnote调正过后还是不对, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50b89577247, createdName=ms2000000503637753, createdTime=Fri Mar 07 10:37:36 CST 2025, time=2025-03-07, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2203530, encodeId=366922035303f, content=请问中药来源的小分子化合物被指出不符合5项规则，要怎么修改，编辑说可以修改后重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6b89216027, createdName=ms8000001555903844, createdTime=Wed May 08 21:11:43 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向：靶点;单体 经验分享：with editor2周多了，要不要催？最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省)]

2022-04-05 姚爪爪

投稿12天了还没有with editor，但是我看拒稿好像很快，是不是没有马上拒都有希望呀

168 25

展开25条回复

[GetPortalCommentsPageByObjectIdResponse(id=2111434, encodeId=d53221114341d, content=偏重的研究方向：中药单体药理 经验分享：请问各位友友这个杂志是什么流程啊怎么编辑从执行编辑—主编—副主编需要这么多编辑审稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a138155158, createdName=ms5000000077211829, createdTime=Wed Jan 25 21:33:06 CST 2023, time=2023-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161584, encodeId=b9132161584f2, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物信息学;动物实验;中药复方 经验分享：投了好多次补了很多实验目前接收了具体时间点为下 2023.9.3 提交 9.29 小修 10.4提交修改稿 10.6接收很看重中药复方的质控化学成分的分析和鉴定最低要求必须有HPLC 图谱复方中药的毒性需要明确急毒实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2feb5587016, createdName=wangc, createdTime=Sun Oct 08 17:52:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2260544, encodeId=74ad2260544a3, content=偏重的研究方向：中药复方机制 经验分享：投一篇中一篇，根本拒不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Apr 15 12:43:49 CST 2025, time=2025-04-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252794, encodeId=82452252e94e5, content=with editor一周了，有没有今年投递的小伙伴, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85169632338, createdName=ms3000001370467208, createdTime=Thu Feb 20 13:25:13 CST 2025, time=2025-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2256895, encodeId=76de225689544, content=请问大家：这个期刊是不是单剂量的中药复方不接收？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc45461785, createdName=ms2000000962134399, createdTime=Thu Mar 20 11:56:19 CST 2025, time=2025-03-20, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1208777, encodeId=de211208e77b8, content=投稿12天了还没有with editor，但是我看拒稿好像很快，是不是没有马上拒都有希望呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/062436adbbcd4e2e890574558d3f2ea4/da27de86c40c4ffa9df1b63d464f7910.jpg, createdBy=884a5513476, createdName=姚爪爪, createdTime=Tue Apr 05 15:28:37 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2255354, encodeId=00ee225535403, content=请问一下这个杂志版面费是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36fa1655811, createdName=1ddd9b98m24(暂无匿称), createdTime=Sun Mar 09 20:44:10 CST 2025, time=2025-03-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2254997, encodeId=dfc0225499e5b, content=偏重的研究方向：网络药理学;中药单体;体内外验证 经验分享：请问编辑让提供质量控制数据，但是是商业化的制剂，已经作为补充文件上传了，但是被编辑退回啦，还是同样的问题，有遇到过的前辈么？要怎么解决呀？还有期刊的参靠文献是什么呀？endnote调正过后还是不对, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50b89577247, createdName=ms2000000503637753, createdTime=Fri Mar 07 10:37:36 CST 2025, time=2025-03-07, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2203530, encodeId=366922035303f, content=请问中药来源的小分子化合物被指出不符合5项规则，要怎么修改，编辑说可以修改后重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6b89216027, createdName=ms8000001555903844, createdTime=Wed May 08 21:11:43 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向：靶点;单体 经验分享：with editor2周多了，要不要催？最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省)]

2025-03-09 1ddd9b98m24(暂无匿称) 来自重庆

请问一下这个杂志版面费是多少啊

17 0

[GetPortalCommentsPageByObjectIdResponse(id=2111434, encodeId=d53221114341d, content=偏重的研究方向：中药单体药理 经验分享：请问各位友友这个杂志是什么流程啊怎么编辑从执行编辑—主编—副主编需要这么多编辑审稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a138155158, createdName=ms5000000077211829, createdTime=Wed Jan 25 21:33:06 CST 2023, time=2023-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161584, encodeId=b9132161584f2, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物信息学;动物实验;中药复方 经验分享：投了好多次补了很多实验目前接收了具体时间点为下 2023.9.3 提交 9.29 小修 10.4提交修改稿 10.6接收很看重中药复方的质控化学成分的分析和鉴定最低要求必须有HPLC 图谱复方中药的毒性需要明确急毒实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2feb5587016, createdName=wangc, createdTime=Sun Oct 08 17:52:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2260544, encodeId=74ad2260544a3, content=偏重的研究方向：中药复方机制 经验分享：投一篇中一篇，根本拒不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Apr 15 12:43:49 CST 2025, time=2025-04-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252794, encodeId=82452252e94e5, content=with editor一周了，有没有今年投递的小伙伴, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85169632338, createdName=ms3000001370467208, createdTime=Thu Feb 20 13:25:13 CST 2025, time=2025-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2256895, encodeId=76de225689544, content=请问大家：这个期刊是不是单剂量的中药复方不接收？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc45461785, createdName=ms2000000962134399, createdTime=Thu Mar 20 11:56:19 CST 2025, time=2025-03-20, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1208777, encodeId=de211208e77b8, content=投稿12天了还没有with editor，但是我看拒稿好像很快，是不是没有马上拒都有希望呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/062436adbbcd4e2e890574558d3f2ea4/da27de86c40c4ffa9df1b63d464f7910.jpg, createdBy=884a5513476, createdName=姚爪爪, createdTime=Tue Apr 05 15:28:37 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2255354, encodeId=00ee225535403, content=请问一下这个杂志版面费是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36fa1655811, createdName=1ddd9b98m24(暂无匿称), createdTime=Sun Mar 09 20:44:10 CST 2025, time=2025-03-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2254997, encodeId=dfc0225499e5b, content=偏重的研究方向：网络药理学;中药单体;体内外验证 经验分享：请问编辑让提供质量控制数据，但是是商业化的制剂，已经作为补充文件上传了，但是被编辑退回啦，还是同样的问题，有遇到过的前辈么？要怎么解决呀？还有期刊的参靠文献是什么呀？endnote调正过后还是不对, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50b89577247, createdName=ms2000000503637753, createdTime=Fri Mar 07 10:37:36 CST 2025, time=2025-03-07, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2203530, encodeId=366922035303f, content=请问中药来源的小分子化合物被指出不符合5项规则，要怎么修改，编辑说可以修改后重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6b89216027, createdName=ms8000001555903844, createdTime=Wed May 08 21:11:43 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向：靶点;单体 经验分享：with editor2周多了，要不要催？最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省)]

2025-03-07 ms2000000503637753 来自贵州省

偏重的研究方向：网络药理学;中药单体;体内外验证
经验分享：请问编辑让提供质量控制数据，但是是商业化的制剂，已经作为补充文件上传了，但是被编辑退回啦，还是同样的问题，有遇到过的前辈么？要怎么解决呀？还有期刊的参靠文献是什么呀？endnote调正过后还是不对

21 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2111434, encodeId=d53221114341d, content=偏重的研究方向：中药单体药理 经验分享：请问各位友友这个杂志是什么流程啊怎么编辑从执行编辑—主编—副主编需要这么多编辑审稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a138155158, createdName=ms5000000077211829, createdTime=Wed Jan 25 21:33:06 CST 2023, time=2023-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161584, encodeId=b9132161584f2, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物信息学;动物实验;中药复方 经验分享：投了好多次补了很多实验目前接收了具体时间点为下 2023.9.3 提交 9.29 小修 10.4提交修改稿 10.6接收很看重中药复方的质控化学成分的分析和鉴定最低要求必须有HPLC 图谱复方中药的毒性需要明确急毒实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2feb5587016, createdName=wangc, createdTime=Sun Oct 08 17:52:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2260544, encodeId=74ad2260544a3, content=偏重的研究方向：中药复方机制 经验分享：投一篇中一篇，根本拒不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Apr 15 12:43:49 CST 2025, time=2025-04-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252794, encodeId=82452252e94e5, content=with editor一周了，有没有今年投递的小伙伴, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85169632338, createdName=ms3000001370467208, createdTime=Thu Feb 20 13:25:13 CST 2025, time=2025-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2256895, encodeId=76de225689544, content=请问大家：这个期刊是不是单剂量的中药复方不接收？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc45461785, createdName=ms2000000962134399, createdTime=Thu Mar 20 11:56:19 CST 2025, time=2025-03-20, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1208777, encodeId=de211208e77b8, content=投稿12天了还没有with editor，但是我看拒稿好像很快，是不是没有马上拒都有希望呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/062436adbbcd4e2e890574558d3f2ea4/da27de86c40c4ffa9df1b63d464f7910.jpg, createdBy=884a5513476, createdName=姚爪爪, createdTime=Tue Apr 05 15:28:37 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2255354, encodeId=00ee225535403, content=请问一下这个杂志版面费是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36fa1655811, createdName=1ddd9b98m24(暂无匿称), createdTime=Sun Mar 09 20:44:10 CST 2025, time=2025-03-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2254997, encodeId=dfc0225499e5b, content=偏重的研究方向：网络药理学;中药单体;体内外验证 经验分享：请问编辑让提供质量控制数据，但是是商业化的制剂，已经作为补充文件上传了，但是被编辑退回啦，还是同样的问题，有遇到过的前辈么？要怎么解决呀？还有期刊的参靠文献是什么呀？endnote调正过后还是不对, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50b89577247, createdName=ms2000000503637753, createdTime=Fri Mar 07 10:37:36 CST 2025, time=2025-03-07, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2203530, encodeId=366922035303f, content=请问中药来源的小分子化合物被指出不符合5项规则，要怎么修改，编辑说可以修改后重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6b89216027, createdName=ms8000001555903844, createdTime=Wed May 08 21:11:43 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向：靶点;单体 经验分享：with editor2周多了，要不要催？最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省)]

2024-05-08 ms8000001555903844 来自北京

请问中药来源的小分子化合物被指出不符合5项规则，要怎么修改，编辑说可以修改后重投

123 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2111434, encodeId=d53221114341d, content=偏重的研究方向：中药单体药理 经验分享：请问各位友友这个杂志是什么流程啊怎么编辑从执行编辑—主编—副主编需要这么多编辑审稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a138155158, createdName=ms5000000077211829, createdTime=Wed Jan 25 21:33:06 CST 2023, time=2023-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161584, encodeId=b9132161584f2, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物信息学;动物实验;中药复方 经验分享：投了好多次补了很多实验目前接收了具体时间点为下 2023.9.3 提交 9.29 小修 10.4提交修改稿 10.6接收很看重中药复方的质控化学成分的分析和鉴定最低要求必须有HPLC 图谱复方中药的毒性需要明确急毒实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2feb5587016, createdName=wangc, createdTime=Sun Oct 08 17:52:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2260544, encodeId=74ad2260544a3, content=偏重的研究方向：中药复方机制 经验分享：投一篇中一篇，根本拒不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Tue Apr 15 12:43:49 CST 2025, time=2025-04-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2252794, encodeId=82452252e94e5, content=with editor一周了，有没有今年投递的小伙伴, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85169632338, createdName=ms3000001370467208, createdTime=Thu Feb 20 13:25:13 CST 2025, time=2025-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2256895, encodeId=76de225689544, content=请问大家：这个期刊是不是单剂量的中药复方不接收？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc45461785, createdName=ms2000000962134399, createdTime=Thu Mar 20 11:56:19 CST 2025, time=2025-03-20, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1208777, encodeId=de211208e77b8, content=投稿12天了还没有with editor，但是我看拒稿好像很快，是不是没有马上拒都有希望呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/062436adbbcd4e2e890574558d3f2ea4/da27de86c40c4ffa9df1b63d464f7910.jpg, createdBy=884a5513476, createdName=姚爪爪, createdTime=Tue Apr 05 15:28:37 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2255354, encodeId=00ee225535403, content=请问一下这个杂志版面费是多少啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36fa1655811, createdName=1ddd9b98m24(暂无匿称), createdTime=Sun Mar 09 20:44:10 CST 2025, time=2025-03-09, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2254997, encodeId=dfc0225499e5b, content=偏重的研究方向：网络药理学;中药单体;体内外验证 经验分享：请问编辑让提供质量控制数据，但是是商业化的制剂，已经作为补充文件上传了，但是被编辑退回啦，还是同样的问题，有遇到过的前辈么？要怎么解决呀？还有期刊的参靠文献是什么呀？endnote调正过后还是不对, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50b89577247, createdName=ms2000000503637753, createdTime=Fri Mar 07 10:37:36 CST 2025, time=2025-03-07, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2203530, encodeId=366922035303f, content=请问中药来源的小分子化合物被指出不符合5项规则，要怎么修改，编辑说可以修改后重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6b89216027, createdName=ms8000001555903844, createdTime=Wed May 08 21:11:43 CST 2024, time=2024-05-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向：靶点;单体 经验分享：with editor2周多了，要不要催？最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省)]

2023-12-07 ms9000001673281029 来自云南省

偏重的研究方向：靶点;单体
经验分享：with editor2周多了，要不要催？最近这么慢吗

207 9

展开9条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务